Home » Gilead’s Harvoni Bags Additional Indications From FDA
Gilead’s Harvoni Bags Additional Indications From FDA
The FDA has given Gilead Sciences the green light for two additional indications for Harvoni in chronic hepatitis C patients with advanced liver disease.
The treatment now is approved in combination with ribavirin for 12 weeks for use in genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis. It also was given a thumbs-up for use in HCV genotype 1-infected subjects with decompensated cirrhosis, including those who have undergone liver transplants.
Harvoni was approved by the FDA in October 2014 for the treatment of chronic hepatitis C genotype 1 infection in adults.
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct